Dual inhibition of V600EBRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism
- 28 January 2012
- journal article
- Published by Elsevier BV in Cancer Letters
- Vol. 314 (2), 244-255
- https://doi.org/10.1016/j.canlet.2011.09.037
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Inhibition of Mutated, Activated BRAF in Metastatic MelanomaThe New England Journal of Medicine, 2010
- Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimeticJCI Insight, 2008
- Oncogenic B-RafV600E Inhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and BimOnline Journal of Public Health Informatics, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences of the United States of America, 2008
- Targeting the Mitogen-Activated Protein Kinase Pathway in the Treatment of Malignant MelanomaClinical Cancer Research, 2006
- B-RAF is a therapeutic target in melanomaOncogene, 2004
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- BRAF as a potential therapeutic target in melanoma and other malignanciesCancer Cell, 2003
- Mutations of the BRAF gene in human cancerNature, 2002